文摘
摘要目的:描述萎缩灰质(GM)模式在不同阶段的多发性硬化症(MS)、及其进化超过1年随访。
背景:通用汽车在基于源代码的女士参与是至关重要的形态测量学(座)能够多元通用分解为它们的通用模式密度。
设计/方法:MRI和临床评估得到8个欧洲网站从170年健康对照组(HC)和398 MS患者(34个临床孤立综合征(CIS), 226年复发缓和(RR), 95次要进步(SP)和43主进步(PP)女士)。57 HC和144 MS患者接受了1年随访。基线通用损失,纵向通用萎缩变化,和相关性与残疾和1年临床恶化进行了评估。
结果:座确定26日相关的通用组件,分配给小脑,皮层下,感觉运动、视觉、颞、顶,海马,执行官静息状态和突出网络。HC相比,医学患者显示重要的通用范围萎缩在几乎所有组件(p = -0.04 < 0.001)。CIS患者显示限制通用在皮层下萎缩,小脑,时间和显著的组件vsHC,名RRMS患者表现出广泛的涉及大多数通用组件的通用萎缩。专业患者显示通用损失vsHC主要位于小脑皮层下,感觉运动,突出和额颞区域。这样的组件显示额外的通用在spm萎缩vs名RRMS。女士在1年期,21例(15%)患者临床恶化。通用萎缩明显发展随着时间的推移,医学患者在皮层下,小脑,感觉运动、颞叶和额颞区域。基线高残疾相关(R2= 0.65)较低的归一化脑容量(b =−0.13, p = 0.001),更高的感觉运动通用损失(b =−0.12, p = 0.002)和较长的疾病持续时间(b = 0.09, p = 0.04)。标准化通用卷(优势比= 0.98,p = 0.008)和小脑通用卷(优势比= 0.40,p = 0.01)是独立的预测因子的临床恶化(曲线下的面积= 0.83)。
结论:座了一个微分地区通用的参与在疾病阶段和显著萎缩进展在MS患者1年。感觉运动和通用小脑萎缩能够解释基线残疾和临床恶化。
披露:罗卡博士已经收到个人赔偿咨询、担任科学顾问委员会说,与拜耳或其他活动,Idec, Celgene公司,Genzyme,默克公司Serono,诺华,罗氏,Teva.Dr。Valsasina已收到个人赔偿咨询、担任科学顾问委员会说,或其他活动从ExceMed扬声器的谢礼。博士代表我没有披露。尤文球迷已经收到个人赔偿咨询博士担任科学顾问委员会说,或其他活动与诺华,生原体,默克公司Almirall,罗氏,TEVA.Dr。Zecca已收到个人赔偿咨询、担任科学顾问委员会说,与Abbvie或其他活动,Almirall, Idec, Celgene公司,Genzyme,莉莉,默克公司Serono,诺华,罗氏,梯瓦制药公司。博士·罗维拉已收到个人赔偿咨询,担任科学顾问委员会说,或其他活动与诺华,Sanofi-Genzyme, Icometrix,拜耳,生原体,Neurodiem, Sanofi-Genzyme Merck-Serono。·罗维拉博士已经收到赔偿服务Icometrix董事会。好吃博士已经收到个人赔偿咨询、担任科学顾问委员会说,与多个博士已经收到演讲酬金或其他活动和旅行费用参与科学会议,一直是临床试验指导委员会成员或参与临床试验的顾问委员会与Actelion股价在过去的几年中,Baye。多个博士已经收到了研究支持从多个博士已经收到了从生原体通过该机构研究的支持,默克公司诺华,罗氏,Sanofi-Genzyme梯瓦制药。卡尼博士没有披露。 Dr. Ciccarelli has nothing to disclose. Dr. Matthews has nothing to disclose. Dr. Palace has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck Serono, Biogen Idec, Novartis, Teva, Chugai Pharma and Bayer Schering, Alexion, Roche, Genzyme, MedImmune, EuroImmun, MedDay, Abide and ARGENX.. Dr. Palace has received research support from MS society, Guthie Jackson Foundation, NIHR, Oxford Health Services Research Committee, EDEN, MRC, GMSI, and John Fell. Dr. Gallo has nothing to disclose. Dr. Bisecco has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Genzyme, and Merck. Dr. Lukas has nothing to disclose. Dr. Bellenberg has nothing to disclose. Dr. Barkhof has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with received compensation for consultancy from Bayer, Biogen-IDEC, Merck, Novartis, Sanofi, Roche, Teva, and IXICO. Dr. Barkhof has received research support from received research support from the Dutch Foundation for MS research and the EU (FP7 and IMI)..Dr. Vrenken has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis. Dr. Vrenken has received research support from Merck Serono, Novartis, Pfizer, and Teva. Dr. Preziosa has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen Idec, Novartis and ExceMED. Dr. Filippi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries. Dr. Filippi has received personal compensation in an editorial capacity for Journal of Neurology. Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche,Teva Pharmaceutical Industries.
